Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Data from Diamond Therapeutics’ trial is the first to identify a safe, active and non-psychedelic dosage of psilocybin, which the company says could open the possibility...
Filament Health has been issued two new patents for the extraction and standardisation of natural psilocybin and associated psychedelic compounds.
An increasing amount of research is investigating the efficacy of psychedelic mushrooms for the treatment of a number of health conditions, however, knowledge about how psychedelic...
KGK Science and Nova Mentis Life Science will carry out a Phase 2a clinical trial testing the efficacy of psilocybin microdosing on Fragile X Syndrome.
Mindset Pharma and PharmaAla have entered into an exclusive sales agreement for the sale and distribution of pharmaceutical-grade psilocybin.
Canadian non-profit TheraPsil has announced that patients and medical professionals from across Canada will be reaching out to Parliamentarians to raise awareness of the medical benefits...
Collaborators of Tryp Therapeutics from the University of Michigan will present two scientific posters at the Society for Neuroscience conference.